Aeterna Zentaris Inc.

0.8800-0.0304-3.34%Vol 3.24M1Y Perf 8.59%
Apr 16th, 2021 16:00 DELAYED
BID0.8725 ASK0.8800
Open0.8800 Previous Close0.9104
Pre-Market- After-Market0.87
 - -  -0.01 -1.14%
Target Price
4.50 
Analyst Rating
— 0.00
Potential %
411.36 
Finscreener Ranking
★★★★+ —    57.21
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★     51.15
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★     47.45
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap55.16M 
Earnings Rating
Buy
Price Range Ratio 52W %
17.72 
Earnings Date
5th May 2021

Today's Price Range

0.82000.8950

52W Range

0.29003.62

5 Year PE Ratio Range

-1.1021.90

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-20.00%
1 Month
-34.81%
3 Months
37.50%
6 Months
137.84%
1 Year
8.59%
3 Years
-38.46%
5 Years
-79.25%
10 Years
-99.92%

TickerPriceChg.Chg.%
AEZS0.8800-0.0304-3.34
AAPL134.16-0.3400-0.25
GOOG2 297.761.10000.05
MSFT260.741.24000.48
XOM56.66-0.3200-0.56
WFC43.841.60003.79
JNJ162.241.85001.15
FB306.18-1.6400-0.53
GE13.39-0.1600-1.18
JPM153.301.13000.74
Financial StrengthValueIndustryS&P 500US Markets
5.20
5.60
0.00
0.01
-5.00
Leverage Ratio 4.00
ProfitabilityValueIndustryS&P 500US Markets
36.60
-166.00
-159.70
-1 240.20
-43.44
RevenueValueIndustryS&P 500US Markets
2.48M
0.02
-62.53
31.74
Earnings HistoryEstimateReportedSurprise %
Q03 2020--0.02-
Q02 2020--0.15-
Q01 2020-0.04-
Q04 2019--0.05-
Q03 2019-0.17-0.0288.24
Q02 2019-0.140.01107.14
Q01 20190.04-0.14-450.00
Q04 2018-0.19-0.31-63.16
Earnings Per EndEstimateRevision %Trend
12/2019 QR-0.12-105.48Negative
12/2019 FY-0.41-123.16Negative
3/2020 QR1.681.15KPositive
12/2020 FY1.78378.13Positive
Next Report Date5th May 2021
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume3.24M
Shares Outstanding62.68M
Trades Count7.35K
Dollar Volume10.45M
Avg. Volume18.43M
Avg. Weekly Volume3.86M
Avg. Monthly Volume5.65M
Avg. Quarterly Volume19.67M

Aeterna Zentaris Inc. (NASDAQ: AEZS) stock closed at 0.88 per share at the end of the most recent trading day (a -3.34% change compared to the prior day closing price) with a volume of 3.26M shares and market capitalization of 55.16M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 11 people. Aeterna Zentaris Inc. CEO is Klaus Paulini.

The one-year performance of Aeterna Zentaris Inc. stock is 8.59%, while year-to-date (YTD) performance is 104.65%. AEZS stock has a five-year performance of -79.25%. Its 52-week range is between 0.29 and 3.62, which gives AEZS stock a 52-week price range ratio of 17.72%

Aeterna Zentaris Inc. currently has a PE ratio of -7.70, a price-to-book (PB) ratio of 10.03, a price-to-sale (PS) ratio of 46.03, a price to cashflow ratio of 9.90, a PEG ratio of 2.32, a ROA of -17.34%, a ROC of -59.74% and a ROE of -97.21%. The company’s profit margin is -43.44%, its EBITDA margin is -159.70%, and its revenue ttm is $2.48 Million , which makes it $0.02 revenue per share.

Of the last four earnings reports from Aeterna Zentaris Inc., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Aeterna Zentaris Inc.’s next earnings report date is 05th May 2021.

The consensus rating of Wall Street analysts for Aeterna Zentaris Inc. is (0), with a target price of $4.5, which is +411.36% compared to the current price. The earnings rating for Aeterna Zentaris Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Aeterna Zentaris Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Aeterna Zentaris Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 32.63, ATR14 : 0.18, CCI20 : -192.17, Chaikin Money Flow : -0.25, MACD : -0.08, Money Flow Index : 21.56, ROC : -22.12, RSI : 41.00, STOCH (14,3) : 13.95, STOCH RSI : 0.00, UO : 36.63, Williams %R : -86.05), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Aeterna Zentaris Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
1 (100.00 %)
Moderate Buy
0
0
0 (0.00 %)
Hold
0
0
0 (0.00 %)
Moderate Sell
0
0
0 (0.00 %)
Strong Sell
0
0
0 (0.00 %)
Summary Rating--Strong Buy
1.00

Aeterna Zentaris Inc.

AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company is actively pursuing opportunities to commercialize macimorelin in the EU & the rest of the world.

CEO: Klaus Paulini

Telephone: +1 843 900-3223

Address: 315 Sigma Drive, Summerville 29486, SC, US

Number of employees: 11

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

62%38%

Bearish Bullish

54%46%

Bearish Bullish

58%42%

News

Stocktwits